search
Back to results

Efficacy of Combination Therapy With Minocycline for Treatment of Stenotrophomonas Maltophilia Infections

Primary Purpose

Hospital Infections

Status
Recruiting
Phase
Phase 4
Locations
Thailand
Study Type
Interventional
Intervention
Minocycline
Levofloxacin or Cotrimoxazole
Placebo
Sponsored by
Mahidol University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hospital Infections focused on measuring Minocycline, Stenotrophomonas maltophilia

Eligibility Criteria

18 Years - 95 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The infection caused by Stenotrophomonas maltophilia
  • The duration of treatment approximately between 7-28 days
  • The patients can take minocycline capsule via oral or nasogastric tube feeding.
  • The patients are anticipated to live more than 48 hrs after participation.
  • In case of an antibiotic drug administration for treatment Stenotrophomonas maltophilia beforehand, it should not exceed 48 hrs.
  • All of participants should be willing to join this project.

Exclusion Criteria:

  • Pregnancy and lactation
  • The patients with active hepatitis
  • The patients with history of minocycline allergy

Sites / Locations

  • Faculty of Medicine Siriraj Hospital, Mahidol UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Combination therapy with minocycline

Monotherapy plus placebo

Arm Description

Minocycline oral 50 mg per capsule 4 capsules oral stat then 2 capsules oral every 12 hours duration 7-28 days

Patients were treated Stenotrophomonas maltophilia infection with standard monotherapy either levofloxacin or Trimethoprim/sulfamethoxazole plus placebo

Outcomes

Primary Outcome Measures

mortality rate
mortality rate of S. maltophilia infected patients receiving treatment at day 28

Secondary Outcome Measures

microbiological clearance
we perform culture and staining to assess bacterial clearance after apply the study drug
adverse drug reactions
we assess adverse drug reactions in 2 aspects; nephrotoxicity and hepatotoxicity

Full Information

First Posted
October 7, 2022
Last Updated
January 7, 2023
Sponsor
Mahidol University
search

1. Study Identification

Unique Protocol Identification Number
NCT05575427
Brief Title
Efficacy of Combination Therapy With Minocycline for Treatment of Stenotrophomonas Maltophilia Infections
Official Title
Efficacy of Combination Therapy With Minocycline for Treatment of Stenotrophomonas Maltophilia Infections
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 24, 2022 (Actual)
Primary Completion Date
July 1, 2024 (Anticipated)
Study Completion Date
November 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mahidol University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of the study is to evaluate the efficacy of minocycline for treatment Stenotrophomonas maltophilia infection. The hypothesis of study is the combination therapy with minocycline would be better than the monotherapy for treatment Stenotrophomonas maltophilia infection.
Detailed Description
Investigator inform patient or their relatives about all topics in project, eligible criteria, method, material and monitoring treatment. After patient or their relatives are appreciated to join this project, patients will be randomly allocated to either levofloxacin or cotrimoxazole plus placebo (monotherapy plus placebo) or levofloxacin or cotrimoxazole plus minocycline (combination therapy). Duration of treatment is determined by site and severity of infection, approximately 7-28 days. Sample size calculation, by two independent proportions formula, the investigators estimate the mortality rate about 54 % in monotherapy group and mortality rate about 27 % in combination therapy with minocycline group, with 2-sided 95% Confidence interval; therefore,51 persons are needed each group. The investigators estimate gather data about 112 persons. (56 participants with monotherapy and 56 participants with combination therapy (minocycline plus another antibiotic drug from intervention trial)) The categorical variables are reported as frequencies and percentages, while continuous variables are reported as means ± standard deviations for normally distributed data and median ± range for non-normally distributed data. The data collected from patients are compared using Chi-square tests or Fisher's exact tests for categorical variables and using t-tests or Mann-Whitney U-tests for continuous variables. During the study is performing, all unexpected adverse event definitely report to Siriraj institutional Review Board immediately, in addition to subjects or their relatives.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hospital Infections
Keywords
Minocycline, Stenotrophomonas maltophilia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
A Phase 4 Randomized, Double blind, Placebo Controlled
Masking
ParticipantInvestigator
Masking Description
Double blind, Placebo Controlled
Allocation
Randomized
Enrollment
112 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Combination therapy with minocycline
Arm Type
Experimental
Arm Description
Minocycline oral 50 mg per capsule 4 capsules oral stat then 2 capsules oral every 12 hours duration 7-28 days
Arm Title
Monotherapy plus placebo
Arm Type
Active Comparator
Arm Description
Patients were treated Stenotrophomonas maltophilia infection with standard monotherapy either levofloxacin or Trimethoprim/sulfamethoxazole plus placebo
Intervention Type
Drug
Intervention Name(s)
Minocycline
Other Intervention Name(s)
Mino
Intervention Description
The patients will receive minocycline oral between 7-28 days
Intervention Type
Drug
Intervention Name(s)
Levofloxacin or Cotrimoxazole
Other Intervention Name(s)
Cravit or Bactrim
Intervention Description
The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Capsule without active compound
Primary Outcome Measure Information:
Title
mortality rate
Description
mortality rate of S. maltophilia infected patients receiving treatment at day 28
Time Frame
participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary Outcome Measure Information:
Title
microbiological clearance
Description
we perform culture and staining to assess bacterial clearance after apply the study drug
Time Frame
participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Title
adverse drug reactions
Description
we assess adverse drug reactions in 2 aspects; nephrotoxicity and hepatotoxicity
Time Frame
participants will be followed for the duration of hospital stay, an expected average of 4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The infection caused by Stenotrophomonas maltophilia The duration of treatment approximately between 7-28 days The patients can take minocycline capsule via oral or nasogastric tube feeding. The patients are anticipated to live more than 48 hrs after participation. In case of an antibiotic drug administration for treatment Stenotrophomonas maltophilia beforehand, it should not exceed 48 hrs. All of participants should be willing to join this project. Exclusion Criteria: Pregnancy and lactation The patients with active hepatitis The patients with history of minocycline allergy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tuvanont Pongdumbun, MD
Phone
+66886822000
Email
tuvanontp@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Adhiratha Boonyasiri, MD
Phone
+6624192688
Email
adhiratha.bon@mahidol.ac.th
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adhiratha Boonyasiri, MD
Organizational Affiliation
Department of research, Faculty of Medicine Siriraj hospital, Mahidol University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Faculty of Medicine Siriraj Hospital, Mahidol University
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adhiratha Boonyasiri, MD
Phone
+6624192688
Email
adhiratha.bon@mahidol.ac.th
First Name & Middle Initial & Last Name & Degree
Adhiratha Boonyasiri, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34058337
Citation
Junco SJ, Bowman MC, Turner RB. Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy. Int J Antimicrob Agents. 2021 Aug;58(2):106367. doi: 10.1016/j.ijantimicag.2021.106367. Epub 2021 May 28.
Results Reference
background
PubMed Identifier
32547125
Citation
Insuwanno W, Kiratisin P, Jitmuang A. Stenotrophomonas maltophilia Infections: Clinical Characteristics and Factors Associated with Mortality of Hospitalized Patients. Infect Drug Resist. 2020 May 28;13:1559-1566. doi: 10.2147/IDR.S253949. eCollection 2020.
Results Reference
background

Learn more about this trial

Efficacy of Combination Therapy With Minocycline for Treatment of Stenotrophomonas Maltophilia Infections

We'll reach out to this number within 24 hrs